|
**Overview**: Transplant Infectious Screening Profile Panel**Introduction**: The Transplant Infectious Screening Profile Panel is a diagnostic tool designed for transplant infection screening using serum samples. In India, solid organ/bone marrow transplant recipients face high risk of opportunistic infections (CMV, EBV, BK virus, fungal, viral hepatitis), with donor/recipient screening critical to prevent post-transplant complications (rejection, mortality). High morbidity from under-testing in rural/low-SES transplant candidates, limited advanced labs, delayed prophylaxis leading to severe CMV disease or graft loss. Per transplant practices aligned with ICMR, Indian Society of Organ Transplantation, and National Organ Transplant Programme guidelines, the test employs immunoassay/PCR for 70 parameters (HIV, HBV, HCV, CMV/EBV/HSV/VZV IgG/IgM, Toxoplasma, Rubella, Parvovirus, HHV-6/8, BK/JC virus, Aspergillus, Candida, etc.) over 3â€"5 days with high accuracy, valuable for pre-transplant risk stratification and post-transplant monitoring. This diagnostic falls under infectious disease screening and targets transplant donors/recipients, addressing accurate detection to guide prophylaxis (valganciclovir, antifungals) or donor selection. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive infectious profiling and reducing transplant-related infections. Its serum-based approach ensures reliable multi-pathogen assessment.**Other Names**: Trans Inf Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/molecular diagnostics, compliant with 2025 standards.**Historical Milestone**: Extended pre-transplant serology/PCR standard; in India, mandatory in transplant centers.**Purpose**: The test assesses 70 parameters including HIV-1/2 Ab to guide transplant infection screening, detect donor/recipient risks, inform prophylaxis.**Test Parameters**: 1. HIV-1 Ab, 2. HIV-2 Ab, 3. HBsAg, 4. Anti-HBc, 5. Anti-HBs, 6. HCV Ab, 7. CMV IgG, 8. CMV IgM, 9. EBV IgG, 10. EBV IgM, 11. Toxoplasma IgG, 12. Toxoplasma IgM, 13. Rubella IgG, 14. Rubella IgM, 15. HSV-1 IgG, 16. HSV-1 IgM, 17. HSV-2 IgG, 18. HSV-2 IgM, 19. VZV IgG, 20. VZV IgM, 21. Syphilis TPHA, 22. HTLV-1/2 Ab, 23. BK Virus PCR, 24. JC Virus PCR, 25. Parvovirus B19 IgG, 26. Parvovirus B19 IgM, 27. HHV-6 IgG, 28. HHV-6 IgM, 29. HHV-8 IgG, 30. HHV-8 IgM, 31. Hepatitis A IgM, 32. Hepatitis E IgM, 33. Aspergillus IgG, 34. Aspergillus IgM, 35. Candida IgG, 36. Candida IgM, 37. Cryptococcus Ag, 38. Pneumocystis jirovecii PCR, 39. Legionella Ag, 40. Mycoplasma IgM, 41. Chlamydia IgM, 42. Adenovirus PCR, 43. Enterovirus PCR, 44. Norovirus PCR, 45. Rotavirus Ag, 46. West Nile Virus IgM, 47. Dengue IgG, 48. Dengue IgM, 49. Chikungunya IgM, 50. Zika Virus IgM, 51. EBV PCR, 52. CMV PCR, 53. HBV PCR, 54. HCV PCR, 55. HIV PCR, 56. Toxoplasma PCR, 57. Rubella PCR, 58. HSV PCR, 59. VZV PCR, 60. HHV-6 PCR, 61. HHV-8 PCR, 62. BK Virus IgM, 63. JC Virus IgM, 64. Parvovirus B19 PCR, 65. Hepatitis A PCR, 66. Hepatitis E PCR, 67. Aspergillus PCR, 68. Candida PCR, 69. Mycoplasma PCR, 70. Chlamydia PCR.**Pretest Condition**: No fasting required; patients should be transplant candidates/donors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on transplant type, prior infections.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected infection including graft loss, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive CMV/EBV PCR or IgM indicates high post-transplant risk, necessitating specialist input.**Specialist Consultation**: Transplant physicians should be consulted for management.**Additional Supporting Tests**: Donor/recipient matching, viral load monitoring for confirmation.**Test Limitations**: Extensive but not exhaustive; comprehensive approach required.**References**: Indian Journal of Transplantation 2024, Transplant Studies India 2023. |
